PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34841901-9 2022 FUTURE DIRECTIONS: Among strategies to inhibit the NLRP3 inflammasome, Glyburide, Metformin, PPAR agonists and the DPP-4 inhibitor saxagliptin appear to be closest to clinical translation, as these drugs are already FDA approved for other indications. Glyburide 71-80 NLR family pyrin domain containing 3 Homo sapiens 51-56 35221708-5 2022 The applicability and effectiveness of the CASPorter cell line were tested by co-treatment with Dox and four known CASP1/NLRP3 inhibitors (MCC950, Glyburide, VX-765 and VRT-043198). Glyburide 147-156 NLR family pyrin domain containing 3 Homo sapiens 121-126 34116285-6 2021 The expression of NLRP3 in the EAM + glyburide group was lower than in the EAM2 group (P < 0.05). Glyburide 37-46 NLR family pyrin domain containing 3 Homo sapiens 18-23 34116285-8 2021 NLRP3 was expressed at lower levels in the EAM + glyburide group than in the EAM2 group (P < 0.05). Glyburide 49-58 NLR family pyrin domain containing 3 Homo sapiens 0-5 32202959-4 2020 Therefore, we evaluated the possibility of targeting the NLRP3 inflammasome pathway by glyburide to suppress periodontal pathogen-induced inflammation. Glyburide 87-96 NLR family pyrin domain containing 3 Homo sapiens 57-62 31971103-8 2021 The development of NLRP3 inhibitors was described from the earliest glyburide in 2001 to the latest progress in 2019. Glyburide 68-77 NLR family pyrin domain containing 3 Homo sapiens 19-24 32202959-3 2020 Recently, glyburide, a hypoglycemic sulfonylurea, has been reported to reduce IL-1beta activation by suppressing activation of the NLRP3 inflammasome. Glyburide 10-19 NLR family pyrin domain containing 3 Homo sapiens 131-136 28592027-0 2017 [Glyburide prevents pulmonary artery smooth muscle cell proliferation and migration via inhibiting NLRP3 activation]. Glyburide 1-10 NLR family pyrin domain containing 3 Homo sapiens 99-104 30527115-12 2018 Treatment with Glybenclamide at 200 muM was used to prevent NLRP3 inflammasome activation. Glyburide 15-28 NLR family pyrin domain containing 3 Homo sapiens 60-65 29432801-8 2018 The inhibition assay showed that glybenclamide (a K+ efflux inhibitor that blocks NLRP3 inflammasome activation) and N-benzyloxycarbony-Val-Ala-Asp (O-methyl)-fluoromethylketone (Z-VAD-FMK; a caspase-1 inhibitor) and NLRP3 depletion with siRNAs reduced the levels of IL-1beta and IL-18 release. Glyburide 33-46 NLR family pyrin domain containing 3 Homo sapiens 82-87 29432801-8 2018 The inhibition assay showed that glybenclamide (a K+ efflux inhibitor that blocks NLRP3 inflammasome activation) and N-benzyloxycarbony-Val-Ala-Asp (O-methyl)-fluoromethylketone (Z-VAD-FMK; a caspase-1 inhibitor) and NLRP3 depletion with siRNAs reduced the levels of IL-1beta and IL-18 release. Glyburide 33-46 NLR family pyrin domain containing 3 Homo sapiens 217-222 29056256-0 2017 Glibenclamide inhibits NLRP3 inflammasome-mediated IL-1beta secretion in human trophoblasts. Glyburide 0-13 NLR family pyrin domain containing 3 Homo sapiens 23-28 29056256-8 2017 These findings suggest that trophoblasts can secrete IL-1beta through the NLRP3/caspase-1 pathway, which is suppressed by glibenclamide, and that the TLR4-mediated NLRP3 inflammasome pathway is more likely to be stimulated in undifferentiated than differentiated trophoblasts. Glyburide 122-135 NLR family pyrin domain containing 3 Homo sapiens 74-79 31714001-4 2020 Since glyburide (a specific inhibitor of K+ efflux channels) inhibited the transcription of NLRP3, IL-1beta, and IL-18, the role of K+ efflux in the activation of inflammasomes in APOL1 risk milieu was implicated. Glyburide 6-15 NLR family pyrin domain containing 3 Homo sapiens 92-97 29159877-15 2018 Cell death induced by dental calculus was significantly inhibited by cytochalasin D, z-YVAD-fmk and glyburide, indicating NLRP3 inflammasome involvement. Glyburide 100-109 NLR family pyrin domain containing 3 Homo sapiens 122-127 28592027-1 2017 Objective: To investigate whether glyburide prevents platelet-derived growth factor (PDGF) induced pulmonary artery smooth muscle cells(PASMCs) proliferation and migration via inhibiting nucleotide binding domain leucine-rich repeat-containing receptors protein 3(NLRP3) inflammasome activation. Glyburide 34-43 NLR family pyrin domain containing 3 Homo sapiens 264-269 28592027-10 2017 Conclusion: Glyburide could ameliorate PDGF-induced PASMCs proliferation and migration by inhibiting NLRP3 inflammasome activation. Glyburide 12-21 NLR family pyrin domain containing 3 Homo sapiens 101-106 27614764-5 2016 Moreover, human nasal epithelial cells (HNECs) were used to evaluate the effects of lipopolysaccharide (LPS) and glyburide on NLRP3 inflammasome signaling pathway. Glyburide 113-122 NLR family pyrin domain containing 3 Homo sapiens 126-131 28320833-6 2017 Many molecules produced by adipocytes activate the NLRP3 inflammasome, and the NLRP3 inhibitor, glibenclamide, restored B lymphopoiesis and minimized induction of myeloid cells induced by adipocyte-conditioned medium in vitro. Glyburide 96-109 NLR family pyrin domain containing 3 Homo sapiens 79-84 28740332-4 2017 Glibenclamide might block KATP channel, Sur1-Trpm4 channel, and NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome activation, decrease the production of proinflammatory mediators (TNF-alpha, IL-1beta, and reactive oxygen species), and suppress the accumulation of inflammatory cells. Glyburide 0-13 NLR family pyrin domain containing 3 Homo sapiens 109-114 27614764-9 2016 NLRP3 inflammasome signaling pathway was augmented by LPS but suppressed by glyburide. Glyburide 76-85 NLR family pyrin domain containing 3 Homo sapiens 0-5 27614764-11 2016 NLRP3 inflammasome signaling pathway was augmented by LPS, but suppressed by glyburide. Glyburide 77-86 NLR family pyrin domain containing 3 Homo sapiens 0-5 25639477-6 2015 Both 1,25(OH)2D3 - and 25(OH)D3 induced IL-1beta release from THP-1 cells, and these effects were blocked with application of the caspase-1 inhibitor YVAD and the NLRP3 inhibitors glyburide and Bay 11-7082. Glyburide 180-189 NLR family pyrin domain containing 3 Homo sapiens 163-168 19805629-0 2009 Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. Glyburide 0-9 NLR family pyrin domain containing 3 Homo sapiens 23-32 19805629-0 2009 Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. Glyburide 0-9 NLR family pyrin domain containing 3 Homo sapiens 33-38 19805629-5 2009 In this study, we show that the type 2 diabetes drug glyburide prevented activation of the Cryopyrin inflammasome. Glyburide 53-62 NLR family pyrin domain containing 3 Homo sapiens 91-100 19805629-8 2009 Glyburide analogues inhibit ATP- but not hypothermia-induced IL-1beta secretion from human monocytes expressing familial cold-associated autoinflammatory syndrome-associated Cryopyrin mutations, thus suggesting that inhibition occurs upstream of Cryopyrin. Glyburide 0-9 NLR family pyrin domain containing 3 Homo sapiens 174-183 19805629-8 2009 Glyburide analogues inhibit ATP- but not hypothermia-induced IL-1beta secretion from human monocytes expressing familial cold-associated autoinflammatory syndrome-associated Cryopyrin mutations, thus suggesting that inhibition occurs upstream of Cryopyrin. Glyburide 0-9 NLR family pyrin domain containing 3 Homo sapiens 246-255 19805629-10 2009 Therefore, glyburide is the first identified compound to prevent Cryopyrin activation and microbial ligand-, DAMP-, and crystal-induced IL-1beta secretion. Glyburide 11-20 NLR family pyrin domain containing 3 Homo sapiens 65-74